BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38801793)

  • 21. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
    Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
    Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.
    Wang M; Guan X; Chi Y; Robinson N; Liu JP
    Tuberculosis (Edinb); 2015 Jul; 95(4):364-72. PubMed ID: 25861717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
    Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK
    J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.
    Kurbatova EV; Gammino VM; Bayona J; Becerra MC; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Taylor A; Viiklepp P; Zignol M; Cegielski JP
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1335-43. PubMed ID: 23107633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the Xpert(®) MTB/RIF and GenoType(®) MTBDRplus assays in Georgia.
    Bablishvili N; Tukvadze N; Avaliani Z; Blumberg HM; Kempker RR
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):676-8. PubMed ID: 25946358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: an observational cohort study.
    Hanrahan CF; Dorman SE; Erasmus L; Koornhof H; Coetzee G; Golub JE
    PLoS One; 2012; 7(11):e49898. PubMed ID: 23226229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China.
    Qi W; Harries AD; Hinderaker SG
    Int J Tuberc Lung Dis; 2011 Jan; 15(1):137-9. PubMed ID: 21276311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
    van den Hof S; Tursynbayeva A; Abildaev T; Adenov M; Pak S; Bekembayeva G; Ismailov S
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):526-31. PubMed ID: 23485387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are we justified in treating for multidrug-resistant tuberculosis based on positive follow-up smear results?
    Kumar RS; Kumar AM; Claassens M; Banurekha VV; Sekar G; Venkatesan P; Swaminathan S
    Int J Tuberc Lung Dis; 2014 Apr; 18(4):449-53. PubMed ID: 24670701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidrug-resistant patients receiving treatment in Niger who are infected with M. tuberculosis Cameroon family convert faster in smear and culture than those with M. tuberculosis Ghana family.
    Ejo M; Hassane-Harouna S; Souleymane MB; Lempens P; Dockx J; Uwizeye C; De Rijk P; Decroo T; Diro E; Torrea G; Rigouts L; Piubello A; de Jong BC
    Tuberculosis (Edinb); 2020 May; 122():101922. PubMed ID: 32275231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical evolution of a group of patients with multidrug-resistant TB treated at a referral center in the city of Rio de Janeiro, Brazil.
    Siqueira HR; Freitas FA; Oliveira DN; Barreto AM; Dalcolmo MP; Albano RM
    J Bras Pneumol; 2009 Jan; 35(1):54-62. PubMed ID: 19219331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can mycobacterial katG genetic changes in isoniazid-resistant tuberculosis influence human disease features?
    Escalante P; McKean-Cowdin R; Ramaswamy SV; Williams-Bouyer N; Teeter LD; Jones BE; Graviss EA
    Int J Tuberc Lung Dis; 2013 May; 17(5):644-51. PubMed ID: 23453008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.
    Cavanaugh JS; Kazennyy BY; Nguyen ML; Kiryanova EV; Vitek E; Khorosheva TM; Nemtsova E; Cegielski JP
    Int J Tuberc Lung Dis; 2012 Aug; 16(8):1069-74. PubMed ID: 22691694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk and outcome of multidrug-resistant tuberculosis: vitamin D receptor polymorphisms and serum 25(OH)D.
    Rathored J; Sharma SK; Singh B; Banavaliker JN; Sreenivas V; Srivastava AK; Mohan A; Sachan A; Harinarayan CV; Goswami R
    Int J Tuberc Lung Dis; 2012 Nov; 16(11):1522-8. PubMed ID: 22990231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
    Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors and mortality associated with treatment default in pulmonary tuberculosis.
    Kliiman K; Altraja A
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):454-63. PubMed ID: 20202304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.